OraSure Technologies, Inc. $OSUR Stock Purchased by Gagnon Securities LLC

Gagnon Securities LLC increased its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 14.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,826,604 shares of the medical instruments supplier’s stock after buying an additional 234,457 shares during the period. OraSure Technologies accounts for about 1.2% of Gagnon Securities LLC’s investment portfolio, making the stock its 28th biggest position. Gagnon Securities LLC’s holdings in OraSure Technologies were worth $7,160,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in OraSure Technologies during the second quarter valued at approximately $30,000. Diversify Advisory Services LLC bought a new stake in OraSure Technologies in the 2nd quarter worth approximately $47,000. Diversify Wealth Management LLC bought a new stake in OraSure Technologies in the 1st quarter worth approximately $36,000. Two Sigma Securities LLC bought a new stake in OraSure Technologies in the 2nd quarter worth approximately $55,000. Finally, Headlands Technologies LLC purchased a new stake in shares of OraSure Technologies during the 2nd quarter worth approximately $67,000. 93.50% of the stock is owned by institutional investors.

Key OraSure Technologies News

These are some of the OSUR news items that stood out recently:

• Positive Sentiment: OraSure reported Q3 2026 adjusted earnings per share of a loss of $0.15, better than the consensus estimate of a loss of $0.20. Revenue of $30.91 million was close to the $31.0 million estimate. OraSure Q3 2026 Earnings Call Transcript
• Positive Sentiment: The company reached an agreement with activist investor Altai Capital, reducing the prospect of a costly proxy battle and easing a source of uncertainty for investors. OraSure activist agreement
• Negative Sentiment: Management forecast Q4 revenue of $30 million-$32 million and FY 2026 revenue of $120.4 million, both slightly below analyst consensus of $31.8 million and $121.5 million, respectively. The company also pushed its expected cash-flow break-even timing to the second half of 2027, which could weigh on expectations for profitability and cash use. OraSure Q4 outlook and break-even timing

Wall Street Analyst Weigh In

OSUR has been the subject of a number of research reports. Craig Hallum upgraded OraSure Technologies to a “strong-buy” rating in a research report on Friday, October 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of OraSure Technologies in a research report on Tuesday, September 1st. Zacks Research upgraded shares of OraSure Technologies to a “hold” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

OraSure Technologies Trading Up 6.9%

OSUR opened at $3.56 on Thursday. The firm has a market cap of $245.53 million, a P/E ratio of -5.16 and a beta of 1.08. OraSure Technologies, Inc. has a 12 month low of $2.08 and a 12 month high of $4.58. The stock has a 50-day moving average of $3.72 and a 200 day moving average of $3.54.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Monday, November 9th. The medical instruments supplier reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. OraSure Technologies had a negative return on equity of 19.81% and a negative net margin of 41.73%. The company had revenue of $30.91 million for the quarter, compared to analysts’ expectations of $31.00 million. On average, research analysts forecast that OraSure Technologies, Inc. will post -0.96 earnings per share for the current fiscal year.

About OraSure Technologies

OraSure Technologies, Inc. develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows. Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.